LSTA Stock Analysis: Buy, Sell, or Hold?
LSTA - Lisata Therapeutics, Inc. Common Stock
$1.44
-0.23 (-13.77%)
▼
5d:
-59.15%
30d:
-57.4%
90d:
-55.0%
WAIT
LOW Confidence
Analysis Updated: Jul 27, 2026 12:00 AM ET
Earnings: Aug 06, 2026
8d
Get Alerted When LSTA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: LSTA is down 59.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: LSTA is down 59.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: LSTA is currently trading at $1.44, which is considered oversold relative to its 30-day fair value range of $2.53 to $3.77.
Technical Outlook: Technically, LSTA is in a strong downtrend. The price is currently testing key support at $1.43. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 13.8% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.00 (+78.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, LSTA is in a strong downtrend. The price is currently testing key support at $1.43. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 13.8% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.00 (+78.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.53 -
$3.77
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-13.8%)
- BULLISH: Trading 78.6% below Wall St target ($4.00)
- WARNING: Recommendation downgraded due to -59.1% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$2.53 -
$3.77
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.43
Resistance Level
$3.85
Current Trend
Strong Downtrend
Technical data as of
Jul 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.93
Wall Street Target
$4.00
(+78.6%)
Revenue Growth (YoY)
-90.0%
Share & Embed Analysis
Last updated: July 27, 2026 9:23 PM ET
Data refreshes hourly during market hours. Next update: 10:23 PM
Data refreshes hourly during market hours. Next update: 10:23 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LSTA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$416 | 53 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$283 | 64 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 58 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 51 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 52 HOLD |
